Rinri Therapeutics Secures $1.78 Million Seed Funding for SNHL Cell Therapy

Rinriā€™s underlying technology, based on innovative stem cell research, seeks to reverse neuropathic sensorineural hearing loss (SNHL) through the repair of the damaged cytoarchitecture in the inner ear.